Header Logo

Connection

NAVAL DAVER to Aged

Back to Details
This is a "connection" page, showing publications NAVAL DAVER has written about Aged.
NAVAL DAVER
Connection Strength
2.088
Aged
  1. Clinical characteristics and overall survival among acute myeloid leukemia patients with TP53 gene mutation or chromosome 17p deletion. Am J Hematol. 2023 08; 98(8):1176-1184.
    View in: PubMed
    Score: 0.036
  2. Hypomethylating agent and venetoclax with FLT3 inhibitor "triplet" therapy in older/unfit patients with FLT3 mutated AML. Blood Cancer J. 2022 05 02; 12(5):77.
    View in: PubMed
    Score: 0.033
  3. A phase 1b/2 study of azacitidine with PD-L1 antibody avelumab in relapsed/refractory acute myeloid leukemia. Cancer. 2021 10 15; 127(20):3761-3771.
    View in: PubMed
    Score: 0.031
  4. A Phase I dose-escalation study of DCLL9718S, an antibody-drug conjugate targeting C-type lectin-like molecule-1 (CLL-1) in patients with acute myeloid leukemia. Am J Hematol. 2021 05 01; 96(5):E175-E179.
    View in: PubMed
    Score: 0.031
  5. Distinct Immunophenotypes of T Cells in Bronchoalveolar Lavage Fluid From Leukemia Patients With Immune Checkpoint Inhibitors-Related Pulmonary Complications. Front Immunol. 2020; 11:590494.
    View in: PubMed
    Score: 0.030
  6. Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3-ITD and IDH mutations. Cancer. 2021 02 01; 127(3):381-390.
    View in: PubMed
    Score: 0.030
  7. Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML. J Hematol Oncol. 2020 10 08; 13(1):132.
    View in: PubMed
    Score: 0.030
  8. CPX-351 (vyxeos) in AML. Leuk Lymphoma. 2020 02; 61(2):288-297.
    View in: PubMed
    Score: 0.028
  9. The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia. Cancer. 2019 05 01; 125(9):1470-1481.
    View in: PubMed
    Score: 0.026
  10. Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study. Cancer Discov. 2019 03; 9(3):370-383.
    View in: PubMed
    Score: 0.026
  11. A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis. Blood. 2018 10 18; 132(16):1664-1674.
    View in: PubMed
    Score: 0.026
  12. A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms. Am J Hematol. 2018 02; 93(2):277-285.
    View in: PubMed
    Score: 0.024
  13. Myeloid/lymphoid neoplasms with FGFR1 rearrangement. Leuk Lymphoma. 2018 07; 59(7):1672-1676.
    View in: PubMed
    Score: 0.024
  14. Vosaroxin in combination with decitabine in newly diagnosed older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome. Haematologica. 2017 10; 102(10):1709-1717.
    View in: PubMed
    Score: 0.024
  15. Buparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemias. Am J Hematol. 2017 Jan; 92(1):7-11.
    View in: PubMed
    Score: 0.023
  16. Malignancy-associated hemophagocytic lymphohistiocytosis in adults: Relation to hemophagocytosis, characteristics, and outcomes. Cancer. 2016 09 15; 122(18):2857-66.
    View in: PubMed
    Score: 0.022
  17. A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome. Leukemia. 2016 Feb; 30(2):268-73.
    View in: PubMed
    Score: 0.021
  18. Ruxolitinib in combination with lenalidomide as therapy for patients with myelofibrosis. Haematologica. 2015 Aug; 100(8):1058-63.
    View in: PubMed
    Score: 0.021
  19. Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Haematologica. 2015 May; 100(5):653-61.
    View in: PubMed
    Score: 0.020
  20. Clinical characteristics and outcomes in patients with acute promyelocytic leukaemia and hyperleucocytosis. Br J Haematol. 2015 Mar; 168(5):646-53.
    View in: PubMed
    Score: 0.020
  21. Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia. Leuk Res. 2014 Sep; 38(9):1126-9.
    View in: PubMed
    Score: 0.019
  22. A prognostic model of therapy-related myelodysplastic syndrome for predicting survival and transformation to acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2014 Oct; 14(5):401-10.
    View in: PubMed
    Score: 0.019
  23. Impact of comorbidities by ACE-27 in the revised-IPSS for patients with myelodysplastic syndromes. Am J Hematol. 2014 May; 89(5):509-16.
    View in: PubMed
    Score: 0.019
  24. Modest activity of pomalidomide in patients with myelofibrosis and significant anemia. Leuk Res. 2013 Nov; 37(11):1440-4.
    View in: PubMed
    Score: 0.018
  25. Effect of NPM1 and FLT3 mutations on the outcomes of elderly patients with acute myeloid leukemia receiving standard chemotherapy. Clin Lymphoma Myeloma Leuk. 2013 Aug; 13(4):435-40.
    View in: PubMed
    Score: 0.018
  26. A phase II open-label study of the intravenous administration of homoharringtonine in the treatment of myelodysplastic syndrome. Eur J Cancer Care (Engl). 2013 Sep; 22(5):605-11.
    View in: PubMed
    Score: 0.018
  27. FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemia. Am J Hematol. 2013 Jan; 88(1):56-9.
    View in: PubMed
    Score: 0.017
  28. Bifid liver in a patient with diaphragmatic hernia. Indian J Gastroenterol. 2005 Jan-Feb; 24(1):27-8.
    View in: PubMed
    Score: 0.010
  29. Outcomes of patients with acute myeloid leukemia and bone marrow fibrosis. J Hematol Oncol. 2024 Nov 15; 17(1):112.
    View in: PubMed
    Score: 0.010
  30. Outcomes and genetic dynamics of acute myeloid leukemia at first relapse. Haematologica. 2024 Nov 01; 109(11):3543-3556.
    View in: PubMed
    Score: 0.010
  31. Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: a phase 1b/2 clinical trial and correlative analyses. Nat Cancer. 2024 Oct; 5(10):1515-1533.
    View in: PubMed
    Score: 0.010
  32. A phase 2 trial of mini-hyper-CVD, blinatumomab, and ponatinib in Philadelphia positive acute lymphoblastic leukemia. Am J Hematol. 2024 Nov; 99(11):2229-2232.
    View in: PubMed
    Score: 0.010
  33. Sotatercept for anemia of myelofibrosis: a phase II investigator-initiated study. Haematologica. 2024 08 01; 109(8):2660-2664.
    View in: PubMed
    Score: 0.010
  34. Efficacy and Safety of Gilteritinib versus Sorafenib as Post-Transplant Maintenance in Patients With FLT3-ITD Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk. 2024 Nov; 24(11):e819-e826.
    View in: PubMed
    Score: 0.010
  35. Optical genome mapping improves the accuracy of classification, risk stratification, and personalized treatment strategies for patients with acute myeloid leukemia. Am J Hematol. 2024 Oct; 99(10):1959-1968.
    View in: PubMed
    Score: 0.010
  36. NPM1-mutated myeloid neoplasms are a unique entity not defined by bone marrow blast percentage. Cancer. 2024 Oct 15; 130(20):3452-3462.
    View in: PubMed
    Score: 0.010
  37. Lower intensity therapy with cladribine/low dose cytarabine/venetoclax in older patients with acute myeloid leukemia compares favorably with intensive chemotherapy among patients undergoing allogeneic stem cell transplantation. Cancer. 2024 Oct 01; 130(19):3333-3343.
    View in: PubMed
    Score: 0.010
  38. Phase 1 Study of CK0801 in Treatment of Bone Marrow Failure Syndromes. NEJM Evid. 2024 Jun; 3(6):EVIDoa2300362.
    View in: PubMed
    Score: 0.010
  39. Phase 1 study of azacitidine in combination with quizartinib in patients with FLT3 or CBL mutated MDS and MDS/MPN. Leuk Res. 2024 Jul; 142:107518.
    View in: PubMed
    Score: 0.010
  40. BRAF mutation in myeloid neoplasm: incidences and clinical outcomes. Leuk Lymphoma. 2024 Sep; 65(9):1344-1349.
    View in: PubMed
    Score: 0.010
  41. Exploring the landscape of somatic ASXL2 mutations in myeloid neoplasms: Frequency and clinical implications. Am J Hematol. 2024 07; 99(7):1434-1436.
    View in: PubMed
    Score: 0.010
  42. Characteristics and outcomes of acute myeloid leukaemia patients with baseline CD7 expression. Br J Haematol. 2024 Jun; 204(6):2259-2263.
    View in: PubMed
    Score: 0.010
  43. Combination of dasatinib and venetoclax in newly diagnosed chronic phase chronic myeloid leukemia. Cancer. 2024 Aug 01; 130(15):2652-2659.
    View in: PubMed
    Score: 0.010
  44. Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia: a phase 2 study. Lancet Haematol. 2024 Apr; 11(4):e276-e286.
    View in: PubMed
    Score: 0.009
  45. Influence of co-mutational patterns in disease phenotype and clinical outcomes of chronic myelomonocytic leukemia. Leukemia. 2024 May; 38(5):1178-1181.
    View in: PubMed
    Score: 0.009
  46. Azacitidine Post-transplant Maintenance Improves Disease Progression in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome. Clin Lymphoma Myeloma Leuk. 2024 May; 24(5):e196-e204.
    View in: PubMed
    Score: 0.009
  47. Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre, phase 1/2 study. Lancet Haematol. 2024 Mar; 11(3):e186-e195.
    View in: PubMed
    Score: 0.009
  48. Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3-Mutated AML. J Clin Oncol. 2024 May 01; 42(13):1499-1508.
    View in: PubMed
    Score: 0.009
  49. Venetoclax and Cobimetinib in Relapsed/Refractory AML: A Phase 1b Trial. Clin Lymphoma Myeloma Leuk. 2024 Jun; 24(6):364-374.
    View in: PubMed
    Score: 0.009
  50. Venetoclax abrogates the prognostic impact of splicing factor gene mutations in newly diagnosed acute myeloid leukemia. Blood. 2023 11 09; 142(19):1647-1657.
    View in: PubMed
    Score: 0.009
  51. Impact of type of induction therapy on outcomes in older adults with AML after allogeneic stem cell transplantation. Blood Adv. 2023 07 25; 7(14):3573-3581.
    View in: PubMed
    Score: 0.009
  52. Blastic plasmacytoid dendritic cell neoplasm: a comprehensive review in pediatrics, adolescents, and young adults (AYA) and an update of novel therapies. Leukemia. 2023 09; 37(9):1767-1778.
    View in: PubMed
    Score: 0.009
  53. A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents. J Hematol Oncol. 2023 07 08; 16(1):73.
    View in: PubMed
    Score: 0.009
  54. A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysis. Blood Cancer J. 2023 06 29; 13(1):101.
    View in: PubMed
    Score: 0.009
  55. Evolving trends and outcomes in older patients with acute myeloid leukemia including allogeneic stem cell transplantation. Am J Hematol. 2023 09; 98(9):1383-1393.
    View in: PubMed
    Score: 0.009
  56. Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome. Blood Adv. 2023 06 13; 7(11):2378-2387.
    View in: PubMed
    Score: 0.009
  57. A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLL. Blood Adv. 2023 05 23; 7(10):1958-1966.
    View in: PubMed
    Score: 0.009
  58. Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial. Lancet Haematol. 2023 Jun; 10(6):e433-e444.
    View in: PubMed
    Score: 0.009
  59. Causal linkage of presence of mutant NPM1 to efficacy of novel therapeutic agents against AML cells with mutant NPM1. Leukemia. 2023 06; 37(6):1336-1348.
    View in: PubMed
    Score: 0.009
  60. Validation of the ALFA-1200 model in older patients with AML treated with intensive chemotherapy. Blood Adv. 2023 03 14; 7(5):828-831.
    View in: PubMed
    Score: 0.009
  61. Antibody therapies for the treatment of acute myeloid leukemia: exploring current and emerging therapeutic targets. Expert Opin Investig Drugs. 2023 Feb; 32(2):107-125.
    View in: PubMed
    Score: 0.009
  62. North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need. Blood. 2023 02 09; 141(6):567-578.
    View in: PubMed
    Score: 0.009
  63. Prediction of survival with lower intensity therapy among older patients with acute myeloid leukemia. Cancer. 2023 04 01; 129(7):1017-1029.
    View in: PubMed
    Score: 0.009
  64. Triple combination targeting methyltransferase, BCL-2, and PD-1 facilitates antileukemia responses in acute myeloid leukemia. Cancer. 2023 02 15; 129(4):531-540.
    View in: PubMed
    Score: 0.009
  65. Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial. Lancet Haematol. 2023 Jan; 10(1):e24-e34.
    View in: PubMed
    Score: 0.009
  66. Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia. J Clin Oncol. 2022 11 20; 40(33):3848-3857.
    View in: PubMed
    Score: 0.008
  67. Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed acute myeloid leukemia. Am J Hematol. 2022 08; 97(8):1035-1043.
    View in: PubMed
    Score: 0.008
  68. Urgent cytoreduction for newly diagnosed acute myeloid leukemia patients allows acquisition of pretreatment genomic data and enrollment on investigational clinical trials. Am J Hematol. 2022 07; 97(7):885-894.
    View in: PubMed
    Score: 0.008
  69. An improved index for diagnosis and mortality prediction in malignancy-associated hemophagocytic lymphohistiocytosis. Blood. 2022 02 17; 139(7):1098-1110.
    View in: PubMed
    Score: 0.008
  70. Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure. J Hematol Oncol. 2022 01 29; 15(1):12.
    View in: PubMed
    Score: 0.008
  71. Improved survival of patients with myelofibrosis in the last decade: Single-center experience. Cancer. 2022 04 15; 128(8):1658-1665.
    View in: PubMed
    Score: 0.008
  72. Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy. Blood Cancer J. 2022 01 25; 12(1):10.
    View in: PubMed
    Score: 0.008
  73. Gilteritinib clinical activity in relapsed/refractory FLT3 mutated acute myeloid leukemia previously treated with FLT3 inhibitors. Am J Hematol. 2022 03 01; 97(3):322-328.
    View in: PubMed
    Score: 0.008
  74. Outcomes of acute lymphoblastic leukemia with KMT2A (MLL) rearrangement: the MD Anderson experience. Blood Adv. 2021 12 14; 5(23):5415-5419.
    View in: PubMed
    Score: 0.008
  75. Prediction of early (4-week) mortality in acute myeloid leukemia with intensive chemotherapy. Am J Hematol. 2022 01 01; 97(1):68-78.
    View in: PubMed
    Score: 0.008
  76. Clonal dynamics and clinical implications of postremission clonal hematopoiesis in acute myeloid leukemia. Blood. 2021 11 04; 138(18):1733-1739.
    View in: PubMed
    Score: 0.008
  77. Single cell T cell landscape and T cell receptor repertoire profiling of AML in context of PD-1 blockade therapy. Nat Commun. 2021 10 18; 12(1):6071.
    View in: PubMed
    Score: 0.008
  78. Central nervous system involvement in blastic plasmacytoid dendritic cell neoplasm. Blood. 2021 10 14; 138(15):1373-1377.
    View in: PubMed
    Score: 0.008
  79. Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements. Blood Cancer J. 2021 09 29; 11(9):162.
    View in: PubMed
    Score: 0.008
  80. Chronic myeloid leukemia, BCR-ABL1-positive, carrying NPM1 mutation - First case series from a single institution. Leuk Res. 2021 12; 111:106685.
    View in: PubMed
    Score: 0.008
  81. Development of TP53 mutations over the course of therapy for acute myeloid leukemia. Am J Hematol. 2021 11 01; 96(11):1420-1428.
    View in: PubMed
    Score: 0.008
  82. Phase II study of single-agent nivolumab in patients with myelofibrosis. Ann Hematol. 2021 Dec; 100(12):2957-2960.
    View in: PubMed
    Score: 0.008
  83. Phase II study of azacitidine with pembrolizumab in patients with intermediate-1 or higher-risk myelodysplastic syndrome. Br J Haematol. 2021 11; 195(3):378-387.
    View in: PubMed
    Score: 0.008
  84. Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial. Lancet Haematol. 2021 Aug; 8(8):e552-e561.
    View in: PubMed
    Score: 0.008
  85. Outcomes of TP53-mutant acute myeloid leukemia with decitabine and venetoclax. Cancer. 2021 10 15; 127(20):3772-3781.
    View in: PubMed
    Score: 0.008
  86. Outcomes in patients with newly diagnosed TP53-mutated acute myeloid leukemia with or without venetoclax-based therapy. Cancer. 2021 10 01; 127(19):3541-3551.
    View in: PubMed
    Score: 0.008
  87. Impact of frontline treatment approach on outcomes of myeloid blast phase CML. J Hematol Oncol. 2021 06 15; 14(1):94.
    View in: PubMed
    Score: 0.008
  88. Inotuzumab ozogamicin with bosutinib for relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia or lymphoid blast phase of chronic myeloid leukemia. Am J Hematol. 2021 08 01; 96(8):1000-1007.
    View in: PubMed
    Score: 0.008
  89. Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia. J Clin Oncol. 2021 09 01; 39(25):2768-2778.
    View in: PubMed
    Score: 0.008
  90. Long-term results of low-intensity chemotherapy with clofarabine or cladribine combined with low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia. Am J Hematol. 2021 08 01; 96(8):914-924.
    View in: PubMed
    Score: 0.008
  91. Isavuconazole as Primary Antifungal Prophylaxis in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-label, Prospective, Phase 2 Study. Clin Infect Dis. 2021 05 18; 72(10):1755-1763.
    View in: PubMed
    Score: 0.008
  92. FLT3 inhibitor based induction and allogeneic stem cell transplant in complete remission 1 improve outcomes in patients with newly diagnosed Acute Myeloid Leukemia with very low FLT3 allelic burden. Am J Hematol. 2021 08 01; 96(8):E275-E279.
    View in: PubMed
    Score: 0.008
  93. Clinicopathologic correlates and natural history of atypical chronic myeloid leukemia. Cancer. 2021 09 01; 127(17):3113-3124.
    View in: PubMed
    Score: 0.008
  94. Clinical, genomic, and transcriptomic differences between myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) and myelodysplastic syndrome with ring sideroblasts (MDS-RS). Am J Hematol. 2021 07 01; 96(7):E246-E249.
    View in: PubMed
    Score: 0.008
  95. Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia. Blood Adv. 2021 04 13; 5(7):1876-1883.
    View in: PubMed
    Score: 0.008
  96. An effective chemotherapy-free regimen of ponatinib plus venetoclax for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia. Am J Hematol. 2021 07 01; 96(7):E229-E232.
    View in: PubMed
    Score: 0.008
  97. Activity of venetoclax-based therapy in chronic myelomonocytic leukemia. Leukemia. 2021 05; 35(5):1494-1499.
    View in: PubMed
    Score: 0.008
  98. Autologous CD33-CAR-T cells for treatment of relapsed/refractory acute myelogenous leukemia. Leukemia. 2021 11; 35(11):3282-3286.
    View in: PubMed
    Score: 0.008
  99. Duration of cytopenias with concomitant venetoclax and azole antifungals in acute myeloid leukemia. Cancer. 2021 07 15; 127(14):2489-2499.
    View in: PubMed
    Score: 0.008
  100. Nivolumab maintenance in high-risk acute myeloid leukemia patients: a single-arm, open-label, phase II study. Blood Cancer J. 2021 03 17; 11(3):60.
    View in: PubMed
    Score: 0.008
  101. Flow cytometric immunophenotypic alterations of persistent clonal haematopoiesis in remission bone marrows of patients with NPM1-mutated acute myeloid leukaemia. Br J Haematol. 2021 03; 192(6):1054-1063.
    View in: PubMed
    Score: 0.008
  102. Decitabine and venetoclax for IDH1/2-mutated acute myeloid leukemia. Am J Hematol. 2021 05 01; 96(5):E154-E157.
    View in: PubMed
    Score: 0.008
  103. Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia. Blood Cancer J. 2021 02 01; 11(2):25.
    View in: PubMed
    Score: 0.008
  104. Post-transplantation cyclophosphamide reduces the incidence of acute graft-versus-host disease in patients with acute myeloid leukemia/myelodysplastic syndromes who receive immune checkpoint inhibitors after allogeneic hematopoietic stem cell transplantation. J Immunother Cancer. 2021 02; 9(2).
    View in: PubMed
    Score: 0.008
  105. Phase 2 study of lenalidomide maintenance for patients with high-risk acute myeloid leukemia in remission. Cancer. 2021 06 01; 127(11):1894-1900.
    View in: PubMed
    Score: 0.008
  106. Clinical Significance of Bone Marrow Blast Percentage in Patients With Myelofibrosis and the Effect of Ruxolitinib Therapy. Clin Lymphoma Myeloma Leuk. 2021 05; 21(5):318-327.e6.
    View in: PubMed
    Score: 0.008
  107. Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment-related mortality. Am J Hematol. 2021 03 01; 96(3):282-291.
    View in: PubMed
    Score: 0.008
  108. The LEukemia Artificial Intelligence Program (LEAP) in chronic myeloid leukemia in chronic phase: A model to improve patient outcomes. Am J Hematol. 2021 02 01; 96(2):241-250.
    View in: PubMed
    Score: 0.008
  109. Natural history of newly diagnosed myelodysplastic syndrome with isolated inv(3)/t(3;3). Am J Hematol. 2020 12; 95(12):E326-E329.
    View in: PubMed
    Score: 0.007
  110. Clonal evolution and treatment outcomes in hematopoietic neoplasms arising in patients with germline RUNX1 mutations. Am J Hematol. 2020 11; 95(11):E313-E315.
    View in: PubMed
    Score: 0.007
  111. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. Lancet Haematol. 2020 Oct; 7(10):e724-e736.
    View in: PubMed
    Score: 0.007
  112. Phase 1 study of combinatorial sorafenib, G-CSF, and plerixafor treatment in relapsed/refractory, FLT3-ITD-mutated acute myelogenous leukemia patients. Am J Hematol. 2020 11; 95(11):1296-1303.
    View in: PubMed
    Score: 0.007
  113. Phase I/II study of dasatinib in combination with decitabine in patients with accelerated or blast phase chronic myeloid leukemia. Am J Hematol. 2020 11; 95(11):1288-1295.
    View in: PubMed
    Score: 0.007
  114. Prognostic value of blasts in peripheral blood in myelofibrosis in the ruxolitinib era. Cancer. 2020 10 01; 126(19):4322-4331.
    View in: PubMed
    Score: 0.007
  115. Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial. Lancet Haematol. 2020 Jul; 7(7):e523-e533.
    View in: PubMed
    Score: 0.007
  116. The Clinical impact of PTPN11 mutations in adults with acute myeloid leukemia. Leukemia. 2021 03; 35(3):691-700.
    View in: PubMed
    Score: 0.007
  117. Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality. Leukemia. 2020 11; 34(11):2914-2924.
    View in: PubMed
    Score: 0.007
  118. Characteristics and outcomes of patients with therapy-related acute myeloid leukemia with normal karyotype. Blood Cancer J. 2020 05 04; 10(5):47.
    View in: PubMed
    Score: 0.007
  119. Impact of numerical variation, allele burden, mutation length and co-occurring mutations on the efficacy of tyrosine kinase inhibitors in newly diagnosed FLT3- mutant acute myeloid leukemia. Blood Cancer J. 2020 05 04; 10(5):48.
    View in: PubMed
    Score: 0.007
  120. Phase 2 study of hyper-CMAD with liposomal vincristine for patients with newly diagnosed acute lymphoblastic leukemia. Am J Hematol. 2020 07; 95(7):734-739.
    View in: PubMed
    Score: 0.007
  121. Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens. Blood Adv. 2020 04 14; 4(7):1311-1320.
    View in: PubMed
    Score: 0.007
  122. Venetoclax and BCR-ABL Tyrosine Kinase Inhibitor Combinations: Outcome in Patients with Philadelphia Chromosome-Positive Advanced Myeloid Leukemias. Acta Haematol. 2020; 143(6):567-573.
    View in: PubMed
    Score: 0.007
  123. Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapy. Am J Hematol. 2020 06; 95(6):612-622.
    View in: PubMed
    Score: 0.007
  124. Posttransplantation cyclophosphamide improves transplantation outcomes in patients with AML/MDS who are treated with checkpoint inhibitors. Cancer. 2020 05 15; 126(10):2193-2205.
    View in: PubMed
    Score: 0.007
  125. A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia. Leukemia. 2020 09; 34(9):2489-2492.
    View in: PubMed
    Score: 0.007
  126. Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes. Blood Adv. 2020 02 11; 4(3):482-495.
    View in: PubMed
    Score: 0.007
  127. Is there an optimal conditioning for older patients with AML receiving allogeneic hematopoietic cell transplantation? Blood. 2020 02 06; 135(6):449-452.
    View in: PubMed
    Score: 0.007
  128. Concurrent JAK2 V617F and MPL W515L in myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis. Leuk Lymphoma. 2020 04; 61(4):963-966.
    View in: PubMed
    Score: 0.007
  129. Haploidentical transplantation for acute myeloid leukemia patients with minimal/measurable residual disease at transplantation. Am J Hematol. 2019 12; 94(12):1382-1387.
    View in: PubMed
    Score: 0.007
  130. Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial. Lancet Oncol. 2019 11; 20(11):1544-1555.
    View in: PubMed
    Score: 0.007
  131. Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study. Lancet Haematol. 2019 Sep; 6(9):e480-e488.
    View in: PubMed
    Score: 0.007
  132. Neurotoxic events associated with BCR-ABL1 tyrosine kinase inhibitors: a case series. Leuk Lymphoma. 2019 12; 60(13):3292-3295.
    View in: PubMed
    Score: 0.007
  133. Prognostic significance of baseline FLT3-ITD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenib. Am J Hematol. 2019 09; 94(9):984-991.
    View in: PubMed
    Score: 0.007
  134. Unrecognized fluid overload during induction therapy increases morbidity in patients with acute promyelocytic leukemia. Cancer. 2019 09 15; 125(18):3219-3224.
    View in: PubMed
    Score: 0.007
  135. Outcomes of patients with chronic phase chronic myeloid leukemia (CML-CP) after discontinuation of frontline ponatinib therapy. Leuk Lymphoma. 2019 12; 60(13):3172-3180.
    View in: PubMed
    Score: 0.007
  136. Efficacy and predictors of response of lenalidomide and rituximab in patients with treatment-naive and relapsed CLL. Blood Adv. 2019 05 14; 3(9):1533-1539.
    View in: PubMed
    Score: 0.007
  137. Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis. Cancer. 2019 08 01; 125(15):2579-2586.
    View in: PubMed
    Score: 0.007
  138. Incidence of second malignancies in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors. Int J Hematol. 2019 May; 109(5):545-552.
    View in: PubMed
    Score: 0.007
  139. Phase 1/2 study of DFP-10917 administered by continuous intravenous infusion in patients with recurrent or refractory acute myeloid leukemia. Cancer. 2019 05 15; 125(10):1665-1673.
    View in: PubMed
    Score: 0.007
  140. A phase 2 study of pracinostat combined with ruxolitinib in patients with myelofibrosis. Leuk Lymphoma. 2019 07; 60(7):1767-1774.
    View in: PubMed
    Score: 0.007
  141. Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience. J Hematol Oncol. 2019 01 03; 12(1):1.
    View in: PubMed
    Score: 0.007
  142. Phase II Trial of MEK Inhibitor Binimetinib (MEK162) in RAS-mutant Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk. 2019 03; 19(3):142-148.e1.
    View in: PubMed
    Score: 0.007
  143. Safety and tolerability of lurbinectedin (PM01183) in patients with acute myeloid leukemia and myelodysplastic syndrome. Hematol Oncol. 2019 Feb; 37(1):96-102.
    View in: PubMed
    Score: 0.007
  144. CD123 expression patterns and selective targeting with a CD123-targeted antibody-drug conjugate (IMGN632) in acute lymphoblastic leukemia. Haematologica. 2019 04; 104(4):749-755.
    View in: PubMed
    Score: 0.007
  145. Addition of eltrombopag to immunosuppressive therapy in patients with newly diagnosed aplastic anemia. Cancer. 2018 11 01; 124(21):4192-4201.
    View in: PubMed
    Score: 0.007
  146. Mutational landscape of myelodysplastic/myeloproliferative neoplasm-unclassifiable. Blood. 2018 11 08; 132(19):2100-2103.
    View in: PubMed
    Score: 0.006
  147. Sorafenib Combined with 5-azacytidine in Older Patients with Untreated FLT3-ITD Mutated Acute Myeloid Leukemia. Am J Hematol. 2018 09; 93(9):1136-1141.
    View in: PubMed
    Score: 0.006
  148. Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial. Lancet Haematol. 2018 Sep; 5(9):e411-e421.
    View in: PubMed
    Score: 0.006
  149. A Pilot Trial of Lirilumab With or Without Azacitidine for Patients With Myelodysplastic Syndrome. Clin Lymphoma Myeloma Leuk. 2018 10; 18(10):658-663.e2.
    View in: PubMed
    Score: 0.006
  150. Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategies. Leukemia. 2018 11; 32(11):2388-2398.
    View in: PubMed
    Score: 0.006
  151. Final results of a phase 2, open-label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome. Cancer. 2018 07 01; 124(13):2758-2765.
    View in: PubMed
    Score: 0.006
  152. Results of second salvage therapy in 673 adults with acute myelogenous leukemia treated at a single institution since 2000. Cancer. 2018 06 15; 124(12):2534-2540.
    View in: PubMed
    Score: 0.006
  153. Significance of thrombocytopenia in patients with primary and postessential thrombocythemia/polycythemia vera myelofibrosis. Eur J Haematol. 2018 Mar; 100(3):257-263.
    View in: PubMed
    Score: 0.006
  154. Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study. Lancet Oncol. 2018 02; 19(2):240-248.
    View in: PubMed
    Score: 0.006
  155. Outcome of patients with relapsed/refractory acute lymphoblastic leukemia after blinatumomab failure: No change in the level of CD19 expression. Am J Hematol. 2018 03; 93(3):371-374.
    View in: PubMed
    Score: 0.006
  156. Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies. Am J Hematol. 2018 03; 93(3):401-407.
    View in: PubMed
    Score: 0.006
  157. Prediction for sustained deep molecular response of BCR-ABL1 levels in patients with chronic myeloid leukemia in chronic phase. Cancer. 2018 03 15; 124(6):1160-1168.
    View in: PubMed
    Score: 0.006
  158. Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia. Cancer. 2018 01 15; 124(2):325-334.
    View in: PubMed
    Score: 0.006
  159. Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitors. Am J Hematol. 2018 01; 93(1):84-90.
    View in: PubMed
    Score: 0.006
  160. Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma. Am J Hematol. 2018 01; 93(1):91-99.
    View in: PubMed
    Score: 0.006
  161. Characterization of TP53 mutations in low-grade myelodysplastic syndromes and myelodysplastic syndromes with a non-complex karyotype. Eur J Haematol. 2017 Dec; 99(6):536-543.
    View in: PubMed
    Score: 0.006
  162. Life after ponatinib failure: outcomes of chronic and accelerated phase CML patients who discontinued ponatinib in the salvage setting. Leuk Lymphoma. 2018 06; 59(6):1312-1322.
    View in: PubMed
    Score: 0.006
  163. PET-CT in AML-related hemophagocytic lymphohistiocytosis. Leuk Lymphoma. 2018 06; 59(6):1486-1489.
    View in: PubMed
    Score: 0.006
  164. Clinical outcomes in adult patients with aplastic anemia: A single institution experience. Am J Hematol. 2017 Dec; 92(12):1295-1302.
    View in: PubMed
    Score: 0.006
  165. Achievement of a negative minimal residual disease state after hypomethylating agent therapy in older patients with AML reduces the risk of relapse. Leukemia. 2018 01; 32(1):241-244.
    View in: PubMed
    Score: 0.006
  166. Haploidentical Transplantation for Older Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome. Biol Blood Marrow Transplant. 2018 06; 24(6):1232-1236.
    View in: PubMed
    Score: 0.006
  167. Time to response and survival in hypomethylating agent-treated acute myeloid leukemia. Leuk Lymphoma. 2018 04; 59(4):1012-1015.
    View in: PubMed
    Score: 0.006
  168. Safety and Efficacy of Blinatumomab in Combination With a Tyrosine Kinase Inhibitor for the Treatment of Relapsed Philadelphia Chromosome-positive Leukemia. Clin Lymphoma Myeloma Leuk. 2017 Dec; 17(12):897-901.
    View in: PubMed
    Score: 0.006
  169. Influence of IDH on FLT3-ITD status in newly diagnosed AML. Leukemia. 2017 11; 31(11):2526-2529.
    View in: PubMed
    Score: 0.006
  170. Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients. Cancer. 2017 Nov 15; 123(22):4391-4402.
    View in: PubMed
    Score: 0.006
  171. A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia. Leuk Lymphoma. 2018 04; 59(4):813-820.
    View in: PubMed
    Score: 0.006
  172. A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia. Cancer. 2017 Nov 15; 123(22):4430-4439.
    View in: PubMed
    Score: 0.006
  173. Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation. Blood. 2017 08 31; 130(9):1125-1131.
    View in: PubMed
    Score: 0.006
  174. A phase I study of moxetumomab pasudotox in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia. Br J Haematol. 2018 08; 182(3):442-444.
    View in: PubMed
    Score: 0.006
  175. Minimal residual disease eradication with epigenetic therapy in core binding factor acute myeloid leukemia. Am J Hematol. 2017 Sep; 92(9):845-850.
    View in: PubMed
    Score: 0.006
  176. Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis. Leuk Res. 2017 08; 59:110-116.
    View in: PubMed
    Score: 0.006
  177. Haptoglobin is frequently low in patients with myelofibrosis: Clinical relevance. Leuk Res. 2017 06; 57:85-88.
    View in: PubMed
    Score: 0.006
  178. Characterization of oral and gut microbiome temporal variability in hospitalized cancer patients. Genome Med. 2017 02 28; 9(1):21.
    View in: PubMed
    Score: 0.006
  179. More than 1 TP53 abnormality is a dominant characteristic of pure erythroid leukemia. Blood. 2017 05 04; 129(18):2584-2587.
    View in: PubMed
    Score: 0.006
  180. Relapse risk and survival in patients with FLT3 mutated acute myeloid leukemia undergoing stem cell transplantation. Am J Hematol. 2017 Apr; 92(4):331-337.
    View in: PubMed
    Score: 0.006
  181. Impact of achievement of complete cytogenetic response on outcome in patients with myelodysplastic syndromes treated with hypomethylating agents. Am J Hematol. 2017 Apr; 92(4):351-358.
    View in: PubMed
    Score: 0.006
  182. Poor outcomes associated with +der(22)t(9;22) and -9/9p in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving chemotherapy plus a tyrosine kinase inhibitor. Am J Hematol. 2017 Mar; 92(3):238-243.
    View in: PubMed
    Score: 0.006
  183. Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab. Blood. 2017 03 09; 129(10):1275-1283.
    View in: PubMed
    Score: 0.006
  184. A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials. Leukemia. 2017 02; 31(2):318-324.
    View in: PubMed
    Score: 0.006
  185. Phase 2 study of low-dose clofarabine plus cytarabine for patients with higher-risk myelodysplastic syndrome who have relapsed or are refractory to hypomethylating agents. Cancer. 2017 Feb 15; 123(4):629-637.
    View in: PubMed
    Score: 0.006
  186. Prognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome-negative acute lymphoblastic leukemia in the era of minimal residual disease. Cancer. 2017 02 01; 123(3):459-467.
    View in: PubMed
    Score: 0.006
  187. Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia. Cancer. 2017 02 01; 123(3):426-435.
    View in: PubMed
    Score: 0.006
  188. A propensity score matching analysis of dasatinib and nilotinib as a frontline therapy for patients with chronic myeloid leukemia in chronic phase. Cancer. 2016 Nov 15; 122(21):3336-3343.
    View in: PubMed
    Score: 0.006
  189. Outcome of Patients With Therapy-Related Acute Myeloid Leukemia With or Without a History of Myelodysplasia. Clin Lymphoma Myeloma Leuk. 2016 11; 16(11):616-624.
    View in: PubMed
    Score: 0.006
  190. Clinical use of ruxolitinib in an academic medical center in unselected patients with myeloproliferative neoplasms not on clinical study. Leuk Lymphoma. 2017 04; 58(4):866-871.
    View in: PubMed
    Score: 0.006
  191. Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A propensity score analysis. Cancer. 2016 Dec 01; 122(23):3650-3656.
    View in: PubMed
    Score: 0.006
  192. Comparison of Multiparameter Flow Cytometry Immunophenotypic Analysis and Quantitative RT-PCR for the Detection of Minimal Residual Disease of Core Binding Factor Acute Myeloid Leukemia. Am J Clin Pathol. 2016 Jun; 145(6):769-77.
    View in: PubMed
    Score: 0.006
  193. Frontline therapy with high-dose imatinib versus second generation tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia - a propensity score analysis. Haematologica. 2016 08; 101(8):e324-7.
    View in: PubMed
    Score: 0.006
  194. The role of the gastrointestinal microbiome in infectious complications during induction chemotherapy for acute myeloid leukemia. Cancer. 2016 07 15; 122(14):2186-96.
    View in: PubMed
    Score: 0.005
  195. Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents. Oncotarget. 2016 Mar 22; 7(12):14172-87.
    View in: PubMed
    Score: 0.005
  196. Prognostic impact of persistent cytogenetic abnormalities at complete remission in adult patients with acute lymphoblastic leukemia. Am J Hematol. 2016 Jun; 91(4):385-9.
    View in: PubMed
    Score: 0.005
  197. Clinical Safety and Efficacy of Nilotinib or Dasatinib in Patients With Newly Diagnosed Chronic-Phase Chronic Myelogenous Leukemia and Pre-Existing Liver and/or Renal Dysfunction. Clin Lymphoma Myeloma Leuk. 2016 Mar; 16(3):152-62.
    View in: PubMed
    Score: 0.005
  198. Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors. Cancer. 2016 Jan 15; 122(2):238-48.
    View in: PubMed
    Score: 0.005
  199. Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes. Leuk Res. 2015 Dec; 39(12):1367-74.
    View in: PubMed
    Score: 0.005
  200. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study. Lancet Oncol. 2015 Nov; 16(15):1547-1555.
    View in: PubMed
    Score: 0.005
  201. Improvement in clinical outcome of FLT3 ITD mutated acute myeloid leukemia patients over the last one and a half decade. Am J Hematol. 2015 Nov; 90(11):1065-70.
    View in: PubMed
    Score: 0.005
  202. Ponatinib as first-line treatment for patients with chronic myeloid leukaemia in chronic phase: a phase 2 study. Lancet Haematol. 2015 Sep; 2(9):e376-83.
    View in: PubMed
    Score: 0.005
  203. Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study. Lancet Oncol. 2015 Sep; 16(9):1099-1110.
    View in: PubMed
    Score: 0.005
  204. IDH1 and IDH2 mutations in myelodysplastic syndromes and role in disease progression. Leukemia. 2016 Apr; 30(4):980-4.
    View in: PubMed
    Score: 0.005
  205. Bone marrow necrosis in acute leukemia: Clinical characteristic and outcome. Am J Hematol. 2015 Sep; 90(9):769-73.
    View in: PubMed
    Score: 0.005
  206. Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase. Leuk Res. 2015 Sep; 39(9):950-6.
    View in: PubMed
    Score: 0.005
  207. Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials. Lancet Haematol. 2015 May; 2(5):e186-93.
    View in: PubMed
    Score: 0.005
  208. The clinical significance of negative flow cytometry immunophenotypic results in a morphologically scored positive bone marrow in patients following treatment for acute myeloid leukemia. Am J Hematol. 2015 Jun; 90(6):504-10.
    View in: PubMed
    Score: 0.005
  209. Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome. Am J Hematol. 2015 Apr; 90(4):276-81.
    View in: PubMed
    Score: 0.005
  210. Prognostic significance of the Medical Research Council cytogenetic classification compared with the European LeukaemiaNet risk classification system in acute myeloid leukaemia. Br J Haematol. 2015 Aug; 170(4):590-3.
    View in: PubMed
    Score: 0.005
  211. Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia. Haematologica. 2015 Jul; 100(7):927-34.
    View in: PubMed
    Score: 0.005
  212. Myelopathy following intrathecal chemotherapy in adults: a single institution experience. J Neurooncol. 2015 Apr; 122(2):391-8.
    View in: PubMed
    Score: 0.005
  213. Characteristics of Sweet Syndrome in patients with acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2015 Jun; 15(6):358-363.
    View in: PubMed
    Score: 0.005
  214. Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study. Lancet Haematol. 2015 Jan; 2(1):e12-20.
    View in: PubMed
    Score: 0.005
  215. Phase II study of methotrexate, vincristine, pegylated-asparaginase, and dexamethasone (MOpAD) in patients with relapsed/refractory acute lymphoblastic leukemia. Am J Hematol. 2015 Feb; 90(2):120-4.
    View in: PubMed
    Score: 0.005
  216. Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: a report on behalf of the MDS Clinical Research Consortium. Cancer. 2015 Mar 15; 121(6):876-82.
    View in: PubMed
    Score: 0.005
  217. Incidence of secondary neoplasms in patients with acute promyelocytic leukemia treated with all-trans retinoic acid plus chemotherapy or with all-trans retinoic acid plus arsenic trioxide. Leuk Lymphoma. 2015 May; 56(5):1342-5.
    View in: PubMed
    Score: 0.005
  218. Clinical significance of microcytosis in patients with primary myelofibrosis. Leuk Res. 2014 Oct; 38(10):1212-6.
    View in: PubMed
    Score: 0.005
  219. The effect of decitabine dose modification and myelosuppression on response and survival in patients with myelodysplastic syndromes. Leuk Lymphoma. 2015 Feb; 56(2):390-4.
    View in: PubMed
    Score: 0.005
  220. Characteristics and outcomes of patients with multiple myeloma who develop therapy-related myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2015 Feb; 15(2):110-4.
    View in: PubMed
    Score: 0.005
  221. Allogeneic stem cell transplantation as initial salvage for patients with acute myeloid leukemia refractory to high-dose cytarabine-based induction chemotherapy. Am J Hematol. 2014 Apr; 89(4):395-8.
    View in: PubMed
    Score: 0.005
  222. Prognostic implications of chromosome 17 abnormalities in the context of monosomal karyotype in patients with acute myeloid leukemia and complex cytogenetics. Clin Lymphoma Myeloma Leuk. 2014 Apr; 14(2):163-71.
    View in: PubMed
    Score: 0.005
  223. Myelodysplastic/myeloproliferative neoplasms, unclassifiable (MDS/MPN, U): natural history and clinical outcome by treatment strategy. Leukemia. 2014 Apr; 28(4):958-61.
    View in: PubMed
    Score: 0.005
  224. The combination of hyper-CVAD plus nelarabine as frontline therapy in adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma: MD Anderson Cancer Center experience. Leukemia. 2014 Apr; 28(4):973-5.
    View in: PubMed
    Score: 0.005
  225. Mutated NPM1 in patients with acute myeloid leukemia in remission and relapse. Leuk Lymphoma. 2014 Jun; 55(6):1337-44.
    View in: PubMed
    Score: 0.005
  226. Biological and clinical features of trisomy 21 in adult patients with acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2013 Sep; 13 Suppl 2:S276-81.
    View in: PubMed
    Score: 0.005
  227. Dynamic acquisition of FLT3 or RAS alterations drive a subset of patients with lower risk MDS to secondary AML. Leukemia. 2013 Oct; 27(10):2081-3.
    View in: PubMed
    Score: 0.004
  228. Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. Blood. 2013 Jun 06; 121(23):4655-62.
    View in: PubMed
    Score: 0.004
  229. Allogeneic hematopoietic stem cell transplantation versus hypomethylating agents in patients with myelodysplastic syndrome: a retrospective case-control study. Am J Hematol. 2013 Mar; 88(3):198-200.
    View in: PubMed
    Score: 0.004
  230. Prognostic significance of 11q23 aberrations in adult acute myeloid leukemia and the role of allogeneic stem cell transplantation. Leukemia. 2013 Apr; 27(4):836-42.
    View in: PubMed
    Score: 0.004
  231. Phase 1 study of an anti-CD33 immunotoxin, humanized monoclonal antibody M195 conjugated to recombinant gelonin (HUM-195/rGEL), in patients with advanced myeloid malignancies. Haematologica. 2013 Feb; 98(2):217-21.
    View in: PubMed
    Score: 0.004
  232. Activating internal tandem duplication mutations of the fms-like tyrosine kinase-3 (FLT3-ITD) at complete response and relapse in patients with acute myeloid leukemia. Haematologica. 2012 Aug; 97(8):1242-5.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.